Keywords
Curation
Ncbi
Racine
Curation
Checkpoint
Ncbi
Racine
Ncbi
Exploration
Accueil
Racine
Racine

La maladie de Parkinson au Canada (serveur d'exploration) - Curation (Ncbi)

Index « Keywords » - entrée « Drug Administration Schedule »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Drug Administration Routes < Drug Administration Schedule < Drug Approval  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 16.
Ident.Authors (with country if any)Title
000095 (2000) F. Calon [Canada] ; M. Morissette ; M. Goulet ; R. Grondin ; P J Blanchet ; P J Bédard ; T. Di Paolo125I-CGP 64213 binding to GABA(B) receptors in the brain of monkeys: effect of MPTP and dopaminomimetic treatments.
000173 (2001) G A Metz [Canada] ; T. Farr ; M. Ballermann ; I Q WhishawChronic levodopa therapy does not improve skilled reach accuracy or reach range on a pasta matrix reaching task in 6-OHDA dopamine-depleted (hemi-Parkinson analogue) rats.
000204 (2002) Philip Seeman [Canada]Atypical antipsychotics: mechanism of action.
000293 (2003) Pierre J. Blanchet [Canada]The fluctuating Parkinsonian patient--clinical and pathophysiological aspects.
000378 (2003) Nancy Bélanger [Canada] ; Laurent Grégoire ; Abdallah Hadj Tahar ; Paul J. BédardChronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeys.
000863 (2008) Jiang Yue [Canada] ; Sharon Miksys ; Ewa Hoffmann ; Rachel F. TyndaleChronic nicotine treatment induces rat CYP2D in the brain but not in the liver: an investigation of induction and time course.
000864 (2008) Leonardo Cortese [Canada] ; Michael P. Caligiuri ; Richard Williams ; Peter Schieldrop ; Rahul Manchanda ; Ashok Malla ; Raj HarricharanReduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia.
000955 (2008) Susan H. Fox [Canada] ; Anthony E. LangLevodopa-related motor complications--phenomenology.
000968 (2008) M. Jog [Canada] ; M. Panisset ; O. Suchowersky ; B. Réhel ; R. SchecterNaturalistic evaluation of entacapone in patients with signs and symptoms of L-dopa wearing-off .
000B13 (2009) Sotirios A. Parashos [États-Unis] ; Christopher J. Swearingen ; Kevin M. Biglan ; Ivan Bodis-Wollner ; Grace S. Liang ; G Webster Ross ; Barbara C. Tilley ; Lisa M. ShulmanDeterminants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience.
001221 (2013) Nicolas Morin [Canada] ; Laurent Grégoire ; Marc Morissette ; Sandrine Desrayaud ; Baltazar Gomez-Mancilla ; Fabrizio Gasparini ; Thérèse Di PaoloMPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
001B98 (2016) Priti Gros [Canada] ; Victoria P. Mery [Chili] ; Anne-Louise Lafontaine [Canada] ; Ann Robinson [Canada] ; Andrea Benedetti [Canada] ; R John Kimoff [Canada] ; Marta Kaminska [Canada]Obstructive sleep apnea in Parkinson's disease patients: effect of Sinemet CR taken at bedtime.
001D30 (2015) Eric J. Lenze [États-Unis] ; Benoit H. Mulsant [Canada] ; Daniel M. Blumberger [Canada] ; Jordan F. Karp [États-Unis] ; John W. Newcomer [États-Unis] ; Stewart J. Anderson [États-Unis] ; Mary Amanda Dew [États-Unis] ; Meryl A. Butters [États-Unis] ; Jacqueline A. Stack [États-Unis] ; Amy E. Begley [États-Unis] ; Charles F. Reynolds [États-Unis]Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial.
001D82 (2015) Constant V. M. Verschuur [Pays-Bas] ; S. R. Suwijn [Pays-Bas] ; B. Post [Pays-Bas] ; M. Dijkgraaf [Pays-Bas] ; B. R. Bloem [Pays-Bas] ; J. J. Van Hilten [Pays-Bas] ; T. Van Laar [Pays-Bas] ; G. Tissingh [Pays-Bas] ; G. Deuschl [Allemagne] ; A. E. Lang [Canada] ; R. J. De Haan [Pays-Bas] ; R. M. A. De Bie [Pays-Bas]Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson’s disease: the LEAP-study
002289 (1988) G. Chouinard [Canada]The use of benzodiazepines in the treatment of manic-depressive illness.
002543 (1996) M. Goulet [Canada] ; R. Grondin ; P J Blanchet ; P J Bédard ; T. Di PaoloDyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Ncbi/Curation

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/KwdEn.i -k "Drug Administration Schedule" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/KwdEn.i  \
                -Sk "Drug Administration Schedule" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Ncbi
   |étape=   Curation
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Drug Administration Schedule
}}
Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022